louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06437327: Comparison of Effectiveness Between Active Release Technique and Hold Relax Technique in Patients With Piriformis Syndrome
Official title: Comparison of Effectiveness Between Active Release Technique and Hold Relax Technique in Patients With Piriformis Syndrome
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Piriformis Syndrome
Lead sponsor: Foundation University Islamabad
Sponsor class: OTHER
First posted: 2024-05-31
Enrollment: 40
Sex: ALL
Minimum age (years): 25
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized Controlled Trial
Primary purpose: TREATMENT

Brief summary: This study is a randomized controlled trial and the purpose of this study is to compare the effects between active release technique and hold relax technique in patients with Piriformis syndrome.

Detailed description: The purpose of this study is to compare the effects between active release technique and hold relax technique in patients with piriformis syndrome pain, range of motion, and functional disability, in adults (age: 25-55 years)

1. Numeric pain rating scale
2. Goniometer
3. Oswestry Disability Questionairre Data will be collected before and after the intervention protocol for each participant.

Data collection procedure: Participants of interest would be approached and explained about the research. Informed written consent will be taken. Pre and post-intervention scores will be recorded.

Eligibility criteria: Inclusion criteria:

* Gender: Both male and female
* Individuals aged 25-55 years
* Tenderness to palpation over sciatic foramen
* Positive FAIR Test.

Exclusion criteria :

* History of hip, pelvic, or Femoral fractures.
* Malignancies.
* Avascular necrosis of Femoral head.
* Inflammatory conditions (e.g. Rheumatoid Arthritis)

Primary outcomes:
measure: Pain intensity
timeFrame: 2 weeks
measure: Physical Function using Oswestry disability Questionnaire
timeFrame: 2 weeks
measure: Hip internal rotation range of motion
timeFrame: 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Rawalpindi
country: Pakistan
facility: Foundation University College of Physical Therapy
state: Punjab
Study officials:
References:
Clinical trial NCT00563927: Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0)
Official title: Prospective Randomized Study on Therapeutic Gain Achieved By Addition of Chemotherapy for T1-4N2-3M0 Nasopharyngeal Carcinoma
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Nasopharyngeal Neoplasms
Carcinoma, Squamous Cell
Keywords: Nasopharyngeal Carcinoma
T1-4N2-3M0
Lead sponsor: Hospital Authority, Hong Kong
Sponsor class: OTHER_GOV
Collaborators: name: Hong Kong Nasopharyngeal Cancer Study Group Limited
First posted: 2007-11-26
Enrollment: 340
Sex: ALL
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To test the therapeutic ratio of additional chemotheray on advanced nasopharyngeal carcinoma.


Eligibility criteria: Inclusion Criteria:

* Undifferentiated or non-keratinizing carcinoma
* Tumor staged as N2-3
* No evidence of distant metastasis M0
* Performance status:0-2
* Marrow: WBC \>= 4 and platelet \>= 100
* Renal: creatinine clearance \>= 60
* Informed consent

Exclusion Criteria:

* WHO type I squamous cell carcinoma or adenocarcinoma
* Age \>= 70
* Palliative intent or tumor extent mandating AP opposing facio-cervical fields
* Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years
* Previous radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume
* Previous chemotherapy
* Patient is pregnant or lactating

Primary outcomes:
measure: Failure free survival rate
timeFrame: 5 year
Secondary outcomes:
measure: Disease-specific survival rate
timeFrame: 5-year
measure: Overall survival rate
timeFrame: 5-year
measure: Complication-free rates
timeFrame: 5-year
Other outcomes:
Locations:
city: Hong Kong
country: China
facility: Pamela Youde Nethersole Eastern Hospital
city: Hong Kong
country: China
facility: Queen Elizabeth Hospital
city: Hong Kong
country: China
facility: Queen Mary Hospital
city: Hong Kong
country: China
facility: Tuen Mun Hospital
Study officials:
affiliation: Department of Clinical Oncology, Queen Elizabeth Hospital
name: Wai Hon LAU, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00612027: Trans GERD: Efficacy and Tolerability of Esomeprazol in Patients Under Ordinary Medical Care Conditions
Official title: Trans GERD: Efficacy and Tolerability of Esomeprazol in Patients Under Ordinary Medical Care Conditions
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Gastrointestinal Diseases
Keywords: gastrointestinal disorder
acid associated gastrointestinal symptoms.
esomeprazole therapy in patients with gastrointestinal disorders
patients with acid associated gastrointestinal symptoms
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2008-02-11
Enrollment: 29586
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: general practitioners and internists

Brief summary: Under daily routine conditions and without any intervention by the sponsor regarding the selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non- medicinal therapy, dose, duration, etc.), routine assessments, the participating physicians (i.e. general practitioners and internists) are asked to document relevant data related to esomeprazole therapy in patients with gastrointestinal disorders. Patients with acid associated gastrointestinal symptoms can be included.


Eligibility criteria: Inclusion Criteria:

* patients with gastrointestinal disorders and patients with acid associated gastrointestinal symptoms treated with esomeprazole.

Exclusion Criteria:

* limitiations; possible risks; warnings; contraindications mentioned in the SPC.

Primary outcomes:
measure: efficacy and tolerability of esomeprazole in patients who are treated by general practitioners and internists
timeFrame: proportion of treated subjects without any specific acid associated symptoms at the end of the study; change in intensity of specific acid associated symptoms; incidence of the occurrence of unknown, unexpected and/or rarely occurring adverse events AE.
Secondary outcomes:
measure: evaluation of a diagnosis tool
timeFrame: evaluation of the predictive value of a two items questionnaire on acid associated symptoms
Other outcomes:
Locations:
Study officials:
affiliation: Medical Department AstraZeneca Germany
name: Kai Richter, MD
role: STUDY_CHAIR
References:
Clinical trial NCT05880927: Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer
Official title: Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer: an Open-label, Multi-center Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Breast Cancer
Lead sponsor: Taizhou Hospital
Sponsor class: OTHER
First posted: 2023-05-30
Enrollment: 150
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This trial is a multicenter, open-label, phase II trial conducted at 23 centers in China. High-risk HER2 positive patients receive pyrotinib 400mg/day for one year or half year for extented adjuvant therapy.

Detailed description: Patients must meet one of the following criteria: N stage ≥1; T stage ≥2; did not achieve pathological complete response (pCR) after neoadjuvant therapy; had pCR after neoadjuvant therapy but with tumor size ≥ 5cm or N stage ≥2; or tumor size less than 2cm but with high Ki67; histologic grade 3 or with lymph node micrometastasis.

Eligibility criteria: Inclusion Criteria:

1. Women aged 18-75 years old
2. HER2 positive breast cancer
3. ECOG PS 0-1
4. Known hormone receptor status
5. Completed 1 year of trastuzumab-based adjuvant therapy within 6 months
6. Patients at high risk

Exclusion Criteria:

1. Serious heart disease or discomfort
2. Inability to swallow, intestinal obstruction, or the presence of other factors that interfere with drug administration and absorption
3. Known allergic history of drug components of this regimen
4. A history of immunodeficiency, including HIV positive, or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation
5. Pregnant and lactating female patients

Primary outcomes:
measure: iDFS
timeFrame: From date of receiving drug until the date of first documented invasive disease or date of death from any cause, whichever came first, assessed up to 60 months
Secondary outcomes:
measure: OS
timeFrame: From date of receiving drug until the date of death from any cause, assessed up to 60 months
measure: Adverse events
timeFrame: through study completion, an average of 5 years
Other outcomes:
Locations:
city: Taizhou
country: China
facility: Taizhou Hospital
state: Zhejiang
Study officials:
affiliation: Taizhou Hospital
name: Feilin Cao, Master
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT07004127: Pneumocystis in Patients Over 75 Year
Official title: Pneumocystis in Non-HIV Patients Over 75 Years Old: Epidemiological, Diagnostic, Microbiological and Therapeutic Characteristics
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pneumocystis
Lead sponsor: Centre Hospitalier Universitaire de Nīmes
Sponsor class: OTHER
First posted: 2025-06-04
Enrollment: 162
Sex: ALL
Minimum age (years): 75
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: geriatric patient with pneumocystis, not HIV positive, over 75 years old

Brief summary: Pneumocystis pneumonia is an infectious disease caused by Pneumocystis jirovecii that affects the lung parenchyma preferentially. Historically described in an immunocompromised population through HIV.

Worldwide, the profile of patients affected by this pathology is changing due to two main factors:

* The sustainable stabilization of HIV patients.
* The emergence of new risk factors of immunosuppression. The geriatric population is particularly affected by these risk factors, increasing the incidence of pneumocystis in this population, which does not have HIV (solid cancer, hemopathy, immunosuppressive treatments, etc.).

There is currently no work specifically studying pneumocystis in this age group. The main objective of this study is to describe the clinical, biological and therapeutic data of a cohort of geriatric patients with pneumocystis, not carrying HIV, from January 1, 2010 to December 31, 2021, in all the centers surveyed.


Eligibility criteria: Inclusion Criteria

1. Patient \> or equal to 75 years of age
2. Microbiological diagnosis:

   * Direct examination with standard stain, finding trophozoite and/or P.jirovecii cyst (BAL or induced sputum) And/or
   * Direct examination with immunofluorescence, finding trophozoite and/or P.jirovecii cyst (BAL or induced sputum)
   * And/or
   * Positive PCR (BAL, sputum, nasopharyngeal swab or blood) and CT \< 35
3. Absence of HIV infection
4. Hospitalization in French hospitals between 2010 and 2021

Non-inclusion criteria

1. Opposition of the patient to participate to the study

Primary outcomes:
measure: Clinical data
timeFrame: From DAY 0 to end of treatment
measure: Therapeutic data
timeFrame: From DAY 0 to end of treatment
measure: Biological data
timeFrame: From DAY 0 to end of treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Nimes
country: France
facility: CHU de NIMES
Study officials:
affiliation: CHU NIMES
name: Adrien BARRAUD
role: PRINCIPAL_INVESTIGATOR
affiliation: CHU NIMES
name: Albert SOTTO, Md, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03122327: cGA in Newly-diagnosed Elderly MM Patients: a Multi-center, Prospective, Non-interventional Study.
Official title: Comprehensive Geriatric Assessment (cGA) in Newly-diagnosed Elderly Multiple Myeloma (MM) Patients: a Multi-center, Prospective, Non-interventional Study.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Multiple Myeloma
Comprehensive Geriatric Assessment
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
First posted: 2017-04-20
Enrollment: 200
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Newly diagnosed Multiple myeloma (MM) patients\>=65 years old

Brief summary: This is a multi-center, prospective, non-interventional study. Eligible newly diagnosed elderly multiple myeloma (MM) patients will receive comprehensive geriatric assessment (cGA) including ECOG scale, questionaires of ADL（activities of daily living), IADL(instrumental ADL),MNA-SF(mini-nutritional assessment), GDS(geriatric depression scale), MMSE(mini-mental state examination), SF-36 and CCI (charlson comorbidity index). Patients will get standard care for MM and receive the above assessments at baseline and after cycle 1, 4 and 12 for treating MM.Follow-up information and survival data of these MM patients would be collected. We would evaluate the cGA status of these newly diagnosed elderly MM patients and investigate the association of cGA parameters with patient's survival.

Detailed description: Baseline: ECOG, ADL, IADL, MNA-SF, GDS, MMSE, SF-36 and CCI; After cycle 1: ECOG,ADL,IADL,GDS and SF-36 After cycle 4: ECOG,ADL,IADL,GDS, MNA-SF and SF-36 After cycle 12: ECOG,ADL,IADL,GDS, MNA-SF and SF-36

Eligibility criteria: Inclusion Criteria:

* age\>=65 years old;
* newly diagnosed and untreated MM patients;
* able to provide informed consent

Exclusion Criteria:

* refused to participate;
* with concomitant amyloidosis;
* smoldering MM.

Primary outcomes:
measure: Current status of cGA in newly diagnosed elderly MM patients
timeFrame: 12 cycles of MM treatment (about 12 months) after the last patient begins treatment
Secondary outcomes:
measure: Association between the baseline cGA parameters and patients' overall survival
timeFrame: 5 years after the last patient begins treatment for MM
measure: Association between baseline cGA parameters and patients' progression free survival
timeFrame: 5 years after the last patient begins treatment for MM
Other outcomes:
Locations:
Study officials:
References:
citation: Yao Y, Sui WW, Liao AJ, Wang W, Chen LJ, Chu XX, Bao L, Cen XN, Fu R, Liu H, Sun CY, Jin FY, Yan H, Wang LQ, Yuan CL, Gao GX, Gao D, Zhang JQ, He JX, Hu JD, Ma LM, Zhang L, Zhou DB, Zou DH, Li J. Comprehensive geriatric assessment in newly diagnosed older myeloma patients: a multicentre, prospective, non-interventional study. Age Ageing. 2022 Jan 6;51(1):afab211. doi: 10.1093/ageing/afab211.
Clinical trial NCT00422760: A 75 Year Old With Dyspnea a Case Report.Observational Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Esophageal Perforation
Keywords: esophageal perforation
COPD
Lead sponsor: Stanley Medical College
Sponsor class: OTHER_GOV
First posted: 2007-01-17
Enrollment: 1
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: DEFINED_POPULATION
Time perspective: RETROSPECTIVE

Brief summary: Clinical Case report Of spontaneous esophageal perforation in a 75 year old man. He prsented with breathlessness and on investigation found to have esophageal perforation

Detailed description: Boerhaave's syndrome represents a diagnostic dilemma for the physician. Boerhaave's syndrome is an uncommon condition where there is oesophageal rupture following forceful vomiting. We report a case of spontaneous rupture of the esophagus in 75-year-old male with chronic obstructive pulmonary disease who was referred to our hospital with acute onset of breathlessness. The absence of vomiting prior to presentation is the distinguishing feature of this particular case.

Eligibility criteria: Inclusion Criteria:

* male with esophageal perforation man with COPD

Exclusion Criteria:

* Iatrogenic perforation

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Stanley medicl college
name: Tiroporur G Balachandar, McH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03241160: Chewing Disorders, Gross Motor Function and Trunk Control in Cerebral Palsy
Official title: The Severity of Chewing Disorders is Related to Gross Motor Function and Trunk Control in Cerebral Palsy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cerebral Palsy
Lead sponsor: Hacettepe University
Sponsor class: OTHER
First posted: 2017-08-07
Enrollment: 119
Sex: ALL
Minimum age (years): 2
Maximum age (years): 12
Standard ages: CHILD
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children with a diagnosis of spastic cerebral palsy

Brief summary: The study is planned to determine the relationship between chewing performance level and gross motor function, and trunk postural control in cerebral palsy (CP).

Detailed description: The study is planned to determine the relationship between chewing performance level and gross motor function, and trunk postural control in cerebral palsy (CP). Chewing performance level will be determined by the chewing performance scale. The Gross Motor Function Classification System (GMFCS) will be used to determine gross motor function levels. Segmental Assessment of Trunk Control (SATCo) will be used to measure trunk control. The correlations between chewing performance level and gross motor function, and trunk postural control will be assessed. The Chi-square test will also be used to compare GMFCS levels and trunk control in children with and without chewing disorders.

Eligibility criteria: Inclusion Criteria:

* Having a diagnosis of cerebral palsy
* Referring by a pediatric neurologist
* Aging between 2 to 12 years

Exclusion Criteria:

* Aging under the age of 24 months
* Using any medicine and/or oral appliances that could affect the chewing performance

Primary outcomes:
measure: Chewing evaluation
timeFrame: 15 days
Secondary outcomes:
measure: Gross motor function evaluation
timeFrame: 15 days
measure: Trunk control evaluation
timeFrame: 15 days
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Hacetttepe University
Study officials:
affiliation: Hacettepe University
name: SELEN SEREL ARSLAN
role: PRINCIPAL_INVESTIGATOR
References:
citation: Serel Arslan S, Demir N, Inal O, Karaduman AA. The severity of chewing disorders is related to gross motor function and trunk control in children with cerebral palsy. Somatosens Mot Res. 2018 Sep-Dec;35(3-4):178-182. doi: 10.1080/08990220.2018.1521788. Epub 2018 Dec 28.
Clinical trial NCT01363960: Retinopathy of Prematurity:Summary of a Decade
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Retinopathy of Prematurity
Keywords: Incidence
neonatal care
retinopathy of prematurity
risk factors
Lead sponsor: Saglik Bilimleri Universitesi Gulhane Tip Fakultesi
Sponsor class: OTHER
First posted: 2011-06-02
Enrollment: 609
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Sampling method: PROBABILITY_SAMPLE
Study population: neonates with Retinopathy of of prematurity

Brief summary: The aim of the study is to evaluate our 10 year experience of retinopathy of prematurity screening.


Eligibility criteria: Inclusion Criteria:

* Neonates either with a BW of less than 1501 gram (g) or born at a GA of 34 weeks (wk) or less
* selected infants with an unstable clinical course were included

Primary outcomes:
measure: Number of neonates developed retinopathy of prematurity
timeFrame: ten years
measure: risk factors contributing to ROP development
timeFrame: ten years
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Gulhane Military Medical School Training Hospital
Study officials:
References:
Clinical trial NCT04664660: Endometriosis and Obstetric Outcomes
Official title: Endometriosis and Risk Factors in Pregnancy, Labor and Delivery
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Endometriosis
Obstetric Complication
Keywords: Endometriosis
Obstetric outcome
Delivery outcome
Neonatal outcome
Lead sponsor: Azienda Ospedaliero-Universitaria di Modena
Sponsor class: OTHER
First posted: 2020-12-11
Enrollment: 350
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pregnant women who delivered at Azienda Ospedaliero Universitaria Policlinico di Modena from 2000 to 2020. Women with a histological diagnosis of endometriosis before pregnancy matched by age with healthy controls.

Brief summary: The purpose of this study is to assess if endometriosis can be considered a risk factor for adverse obstetric and delivery outcomes

Detailed description: This is a retrospective, observational, case-control study. Pregnancy, delivery and neonatal outcomes will be analyzed in two groups of patients (case and control group): women with diagnosis of endometriosis histologically confirmed and women without endometriosis. Women with endometriosis will be matched to controls by age. A database with general medical and gynecological history, pregnancy course, delivery mode and newborn conditions will be analyzed.

Eligibility criteria: Inclusion Criteria:

* Pregnant women who delivered at Azienda Ospedaliero Universitaria Policlinico di Modena from 2000 to 2020
* Histologic diagnosis of endometriosis before pregnancy for case group
* Age matched healthy patients for control group

Exclusion Criteria:

* Clinical records not available

Primary outcomes:
measure: Preterm delivery
timeFrame: Time of delivery
measure: Gestational diabetes
timeFrame: after 18 weeks' pregnancy
measure: Gestational hypertension
timeFrame: after 20 weeks' gestation
measure: Assisted reproduction technologies
timeFrame: before pregnancy
measure: Cesarean Section
timeFrame: Time of delivery
measure: Postpartum hemorrhage
timeFrame: Time of delivery
measure: Birth-weight
timeFrame: Time of delivery
measure: Apgar scores
timeFrame: Time of delivery
Secondary outcomes:
Other outcomes:
Locations:
city: Modena
country: Italy
facility: Carlo Alboni
Study officials:
References: